Suggestions
Mark Gorelick
Chief Product Officer at CardieX Limited
Mark Gorelick, PhD, is the Chief Product Officer at CardieX Limited, a global health technology company focusing on hypertension, cardiovascular disease, and other vascular health disorders.1 He joined CardieX in December 2020 and has since been responsible for managing product development for a wide range of FDA and HIPAA compliant products, including hardware and software solutions.1
Key aspects of Mark Gorelick's role and achievements at CardieX include:
- Successfully obtaining FDA 510(k) clearance for a World-First Vascular Biometric Health Monitor.1
- Leading an award-winning product team that received the CES Innovation Award 2023 and PC Mag Best of CES 2023.1
- Launching a first-of-its-kind consumer product to validate the company's proprietary technology.1
- Introducing a new customer health-focused brand, CONNEQT Health, which focuses on clinical and consumer FDA compliant health solutions.1
Prior to joining CardieX, Mark Gorelick held several notable positions:
- Founder/Managing Partner at XPhys Technologies Inc. (2007 - Present)1
- Chief Product Officer at Traction Health Inc. (June 2019 - July 2023)1
- Chief Product Officer at Step Health (March 2018 - June 2019)1
- VP, Digital Health at Performance Lab (2018 - 2019)1
- Chief Science Officer at PAI Health (September 2015 - March 2018)1
Mark Gorelick has a strong background in digital health, product development, and innovation strategy. His experience spans across various aspects of the health technology industry, including consumer wearables, software applications, and data analytics.1
Highlights
A nice summary article from Scientific American - The Biggest Health and Medicine Stories of 2023
Quick summary:
🌐 Advancements in Weight-Loss Drugs: New generation drugs like Wegovy and Ozempic show potential benefits beyond weight loss, including heart attack and stroke risk reduction.
🩹 End of COVID Public Health Emergency: The federal public health emergency for COVID concluded on May 11, transitioning to long-term management despite the ongoing circulation of the virus.
🐷 Progress in Xenotransplants: Scientists made strides in xenotransplants, with the second-ever transplant of a genetically engineered pig heart and successful experiments in other animals.
💉 Approval of RSV Vaccines: Safe and effective vaccines for respiratory syncytial virus (RSV) were approved by the FDA, protecting pregnant individuals, older adults, and children.
🧬 Milestone in CRISPR Gene Editing: The FDA approved the first CRISPR-based treatment, exa-cel, for sickle cell disease, deactivating a faulty gene and preventing symptoms in clinical trials.
🩺 Insights into Long COVID: Long COVID, resembling a neurological disease, was better understood, showing cognitive and autonomic nervous system-related symptoms.
🤖 Integration of AI in Medicine: Chat-based AI systems, including ChatGPT, entered medicine, offering potential in diagnosis and therapy, though caution is advised.
👁️ Groundbreaking Face and Eye Transplant: The first partial face and whole-eye transplant provided hope for restoring appearance and function in individuals with traumatic eye injuries.
#HealthInnovation #MedicalAdvancements #ScienceBreakthroughs #HealthTech #MedicalResearch
Health experts are redefining cardiovascular disease (CVD) risk, prevention, and management based on a new American Heart Association advisory. They have identified strong connections between CVD, kidney disease, Type 2 diabetes, and obesity, proposing the term "cardiovascular-kidney-metabolic (CKM) syndrome." The advisory introduces CKM syndrome stages, emphasizes social factors' impact on health, promotes collaborative care approaches, and suggests updates to the risk prediction algorithm for heart attack, stroke, and heart failure. #HeartDisease #CardiovascularHealth #Diabetes #KidneyDisease #CKMSyndrome #Healthcare #Prevention #RiskFactors #AmericanHeartAssociation
